Korean study tracks approved liver cancer drugs in real patients
NCT ID NCT06544629
Summary
This study monitors the safety and effectiveness of two already-approved liver cancer drugs (Imjudo and Imfinzi) in real-world medical practice in Korea. It will follow 246 patients who are receiving these drugs as part of their standard cancer treatment. The goal is to collect information on side effects and how well the drugs work outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBusan, South Korea
-
Research Site
RECRUITINGGoyang, South Korea
-
Research Site
RECRUITINGSeongnam, South Korea
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
NOT_YET_RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGSuwon, South Korea
Conditions
Explore the condition pages connected to this study.